HomeCompareRSPI vs PEP

RSPI vs PEP: Dividend Comparison 2026

RSPI yields 111111.11% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RSPI wins by $1.3838190899465547e+27M in total portfolio value
10 years
RSPI
RSPI
● Live price
111111.11%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.3838190899465547e+27M
Annual income
$1,381,373,456,343,941,000,000,000,000,000,000.00
Full RSPI calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — RSPI vs PEP

📍 RSPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSPIPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSPI + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSPI pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSPI
Annual income on $10K today (after 15% tax)
$9,444,444.44/yr
After 10yr DRIP, annual income (after tax)
$1,174,167,437,892,349,800,000,000,000,000,000.00/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, RSPI beats the other by $1,174,167,437,892,349,800,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSPI + PEP for your $10,000?

RSPI: 50%PEP: 50%
100% PEP50/50100% RSPI
Portfolio after 10yr
$6.919095449732774e+26M
Annual income
$690,686,728,171,970,500,000,000,000,000,000.00/yr
Blended yield
99.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

RSPI
No analyst data
Altman Z
-2461.3
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSPI buys
0
PEP buys
6
PoliticianChamberTickerTypeAmountDate
Sheldon Whitehouse🏛 Senate$PEP▼ Sell$1,001 - $15,0002026-02-23
Sheldon Whitehouse🏛 Senate$PEP▼ Sell$1,001 - $15,0002026-02-23
Julia Letlow🏢 House$PEP▲ Buy$1,001 - $15,0002026-02-05
Julie Johnson🏢 House$PEP▼ Sell$1,001 - $15,0002025-12-18
Jared Moskowitz🏢 House$PEP▼ Sell$1,001 - $15,0002025-12-02
Jared Moskowitz🏢 House$PEP▼ Sell$1,001 - $15,0002025-12-02
Jared Moskowitz🏢 House$PEP▼ Sell$15,001 - $50,0002025-12-02
Julie Johnson🏢 House$PEP▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$PEP▲ Buy$1,001 - $15,0002025-11-05
Scott DesJarlais🏢 House$PEP▼ Sell$1,001 - $15,0002025-10-28
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSPIPEP
Forward yield111111.11%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$1.3838190899465547e+27M$144.7K
Annual income after 10y$1,381,373,456,343,941,000,000,000,000,000,000.00$63,430.49
Total dividends collected$1.383658847866035e+27M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: RSPI vs PEP ($10,000, DRIP)

YearRSPI PortfolioRSPI Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$11,121,811$11,111,111.11$10,854$514.44+$11.11MRSPI
2$11,561,029,218$11,549,128,879.66$11,982$758.21+$11561.02MRSPI
3$11,232,204,364,934$11,219,834,063,671.13$13,526$1,136.44+$11232204.35MRSPI
4$10,199,601,320,781,262$10,187,582,862,110,782.00$15,727$1,741.93+$10199601320.77MRSPI
5$8,656,721,364,988,387,000$8,645,807,791,575,153,000.00$19,012$2,750.28+$8656721364988.37MRSPI
6$6,867,176,795,058,000,000,000$6,857,914,103,197,462,000,000.00$24,173$4,514.44+$6867176795058000.00MRSPI
7$5,091,669,942,459,710,000,000,000$5,084,322,063,288,997,000,000,000.00$32,789$7,793.80+$5091669942459709440.00MRSPI
8$3,528,599,356,203,225,300,000,000,000$3,523,151,269,364,793,600,000,000,000.00$48,258$14,354.51+$3.5285993562032256e+21MRSPI
9$2,285,638,880,947,370,600,000,000,000,000$2,281,863,279,636,233,000,000,000,000,000.00$78,586$28,686.63+$2.2856388809473705e+24MRSPI
10$1,383,819,089,946,554,900,000,000,000,000,000$1,381,373,456,343,941,000,000,000,000,000,000.00$144,688$63,430.49+$1.3838190899465547e+27MRSPI

RSPI vs PEP: Complete Analysis 2026

RSPIStock

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Full RSPI Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this RSPI vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSPI vs SCHDRSPI vs JEPIRSPI vs ORSPI vs KORSPI vs MAINRSPI vs MORSPI vs PMRSPI vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.